Struggling Marinus gets a bump out of a positive PhII snapshot
A little more than six months since its stock price was crushed by a failed late-stage program for its leading — and only — drug, tiny biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
